日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Cixutumumab 和 temsirolimus 治疗骨和软组织肉瘤患者：一项多中心、开放标签的 2 期试验

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(13)70049-4
Schwartz Gary K, Tap William D, Qin Li-Xuan, Livingston Michael B, Undevia Samir D, Chmielowski Bartosz, Agulnik Mark, Schuetze Scott M, Reed Damon R, Okuno Scott H, Ludwig Joseph A, Keedy Vicki, Rietschel Petra, Kraft Andrew S, Adkins Douglas, Van Tine Brian A, Brockstein Bruce, Yim Vincent, Bitas Christiana, Abdullah Abdul, Antonescu Cristina R, Condy Mercedes, Dickson Mark A, Vasudeva Shyamprasad Deraje, Ho Alan L, Doyle L Austin, Chen Helen X, Maki Robert G
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

A phase I study of continuous infusion cilengitide in patients with solid tumors

一项针对实体瘤患者的持续输注西伦吉肽的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-010-9537-9
O'Donnell, Peter H; Undevia, Samir D; Stadler, Walter M; Karrison, Theodore M; Nicholas, M Kelly; Janisch, Linda; Ratain, Mark J
发表日期：2012
文献求助 收藏

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

两项关于西罗莫司联合索拉非尼或舒尼替尼治疗晚期恶性肿瘤患者的药物相互作用研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-10-2061
Gangadhar, Tara C; Cohen, Ezra E W; Wu, Kehua; Janisch, Linda; Geary, David; Kocherginsky, Masha; House, Larry K; Ramirez, Jackie; Undevia, Samir D; Maitland, Michael L; Fleming, Gini F; Ratain, Mark J
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

喹喔啉类抗肿瘤药物(R+)XK469抑制神经母细胞瘤的生长

期刊:Pediatric Blood & Cancer
影响因子:2.3
doi:10.1002/pbc.22639
Kakodkar, Nisha C; Peddinti, Radhika; Kletzel, Morris; Tian, Yufeng; Guerrero, Lisa J; Undevia, Samir D; Geary, David; Chlenski, Alexandre; Yang, Qiwei; Salwen, Helen R; Cohn, Susan L
细胞生物学
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy

原发肿瘤坏死可预测局部晚期软组织肉瘤在术前同步放化疗后的远处控制情况

期刊:International Journal of Radiation Oncology Biology Physics
影响因子:6.5
doi:10.1016/j.ijrobp.2009.03.015
MacDermed, Dhara M; Miller, Luke L; Peabody, Terrance D; Simon, Michael A; Luu, Hue H; Haydon, Rex C; Montag, Anthony G; Undevia, Samir D; Connell, Philip P
肿瘤
肿瘤免疫
发表日期：2010
文献求助 收藏

Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease

一项I期研究评估了剂量递增的白消安联合氟达拉滨和阿仑单抗作为异基因造血干细胞移植预处理方案的疗效：高剂量时清除率降低，并出现晚期窦状隙阻塞综合征/静脉闭塞性疾病。

期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.3109/10428194.2010.520773
O'Donnell, Peter H; Artz, Andrew S; Undevia, Samir D; Pai, Rish K; Del Cerro, Paula; Horowitz, Sarah; Godley, Lucy A; Hart, John; Innocenti, Federico; Larson, Richard A; Odenike, Olatoyosi M; Stock, Wendy; Van Besien, Koen
干细胞
发育与干细胞
细胞生物学
发表日期：2010
文献求助 收藏

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas

索拉非尼治疗转移性或复发性肉瘤患者的II期研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2008.20.4495
Maki, Robert G; D'Adamo, David R; Keohan, Mary L; Saulle, Michael; Schuetze, Scott M; Undevia, Samir D; Livingston, Michael B; Cooney, Matthew M; Hensley, Martee L; Mita, Monica M; Takimoto, Chris H; Kraft, Andrew S; Elias, Anthony D; Brockstein, Bruce; Blachère, Nathalie E; Edgar, Mark A; Schwartz, Lawrence H; Qin, Li-Xuan; Antonescu, Cristina R; Schwartz, Gary K
发表日期：2009
文献求助 收藏

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

动态血压监测可在治疗第一天检测到索拉非尼引起的血压升高

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-09-0058
Maitland, Michael L; Kasza, Kristen E; Karrison, Theodore; Moshier, Kristin; Sit, Laura; Black, Henry R; Undevia, Samir D; Stadler, Walter M; Elliott, William J; Ratain, Mark J
发表日期：2009
文献求助 收藏

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9

R(+)XK469抑制CYP2C9对S-华法林的羟基化作用

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2009.04.032
Yong, Wei Peng; Kim, Tae Won; Undevia, Samir D; Innocenti, Federico; Ratain, Mark J
发表日期：2009
文献求助 收藏

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours

喹喔啉类抗肿瘤药物R(+)XK469在晚期实体瘤患者中的I期药代动力学研究

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2008.05.018
Undevia, Samir D; Innocenti, Federico; Ramirez, Jacqueline; House, Larry; Desai, Apurva A; Skoog, Linda A; Singh, Deepti A; Karrison, Theodore; Kindler, Hedy L; Ratain, Mark J
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏